«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2017年第3期

页码:

286-289,296

栏目:

临床研究

出版日期:

2017-01-25

文章信息/Info

Title:

Platelet reactivity in patients with acute coronary syndrome and diabetes mellitus undergoing percutaneous coronary intervention and dual antiplatelet therapy with clopidogrel or ticagrelor

作者:

汪 敏; 双东思; 苏 晞

武汉亚洲心脏病医院心内科，湖北 武汉 430010

Author(s):

WANG Min;  SHUANG Dong-si;  SU Xi

Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan 430010, Hubei, China

关键词:

替格瑞洛; 氯吡格雷; 急性冠脉综合征; 2型糖尿病; 血小板聚集功能

Keywords:

ticagrelor;  clopidogrel;  acute coronary syndrome;  type 2 diabetes mellitus;  platelet aggregation

分类号:

R541.4

DOI:

-

文献标识码:

A

摘要:

目的 观察急性冠脉综合征(ACS)并发2型糖尿病(T2DM)行经皮腔内冠状动脉介入（PCI）治疗患者中替格瑞洛与氯吡格雷对血小板聚集功能影响的比较。方法 回顾性的收集2013年3月~2015年3月我院ACS并发T2DM行PCI患者175例，按使用的抗血小板药物分为两组：替格瑞洛组（n=22）和氯吡格雷组（n=153），采用光比浊法分析血小板聚集功能，比较两者血小板聚集功能的差异。结果 花生四烯酸（AA）诱导的血小板聚集率:氯吡格雷组为（32±20）%，替格瑞洛组为 （26±17）%,两组差异无显著性；二磷酸腺苷（ADP）诱导的血小板聚集率：氯吡格雷组为 （51±18）%，替格瑞洛组（40±18）%,两组有显著性差异（P=0.01）。结论 对于ACS并发T2DM行PCI患者，替格瑞洛较氯吡格雷显著减低ADP诱导的血小板聚集率，不影响AA诱导的血小板聚集率。

Abstract:

AIM To observe the effect of clopidogrel or ticagrelor on platelet aggregation in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM). METHODS A total of 175 patients with ACS and T2DM in Wuhan Asia Heart Hospital were included in this retrospective study. Patients were divided into two groups: ticagrelor group (n=22) and clopidogrel group (n=153). Platelet aggregation function was tested by light transmission platelet aggregation (LTA) and the difference of platelet aggregation function between groups was compared. RESULTS No significant difference was found between groups in arachidonic acid (AA)-induced platelet aggregation rate (32±20)% in clopidogrel group and (26±17)% in ticagrelor group (P=0.160)]. Adenosine diphosphate (ADP)-induced platelet aggregation rate in ticagrelor group was lower than clopidogrel group ［(40±18)% vs.(51±18)%, P=0.01］. CONCLUSION Ticagrelor significantly decreases ADP-induced platelet aggregation rate moreso than clopidogrel in patients with ACS and T2DM, but no significant difference is found in AA-induced platelet aggregation between drugs.

参考文献/References

[1]Leon MB,Baim DS,Popma JJ,et al.A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.Stent Anticoagulation Restenosis Study Investigators[J].N Engl J Med,1998,339(23):1665-1671.
[2]Yusuf S,Zhao F,Mehta SR,et al.for the Clopidigrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J].N Engl J Med,2001,345(7):494-502.
[3]Wiviott SD,Braunwald E,McCabe CH,et al.for the TRITON-TIMI 38 Investigators.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015.
[4]Wallentin L,Becker RC,Budaj A,et al.for the PLATO Investigators,Freij A,Thorsén M.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
[5]Price MJ,Murray SS,Angiolillo DJ,et al.for the GIFT Investigators.Influence of genetic polymorphisms on the effect of high- and standard dose clopidogrel after percutaneous coronary intervention: the GIFT(Genotype Information and Functional Testing)study[J].J Am Coll Cardiol,2012,59(22):1928-1937.
[6]Hochholzer W,Trenk D,Fromm MF,et al.Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement[J].J Am Coll Cardiol,2010,55(22):2427-2434.
[7]Jneid H,Anderson JL,Wright RS,et al.for the American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2012,60(7):645-681.
[8]Price MJ,Coleman JL,Steinhubl SR,et al.Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers[J].Am J Cardiol,2006,98(5):681-684.
[9]Price MJ,Baker BA,Jakubowski JA,et al.Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification[J].J Thromb Haemost,2014,12(4):560-563.
[10]James S,Angiolillo DJ,Cornel JH,et al.for the PLATO Study Group.Ticagrelor vs.clopidogrel in patients with acute coronary syndromes and diabetes:a substudy from the PLATelet inhibition and patient Outcomes(PLATO)trial[J].Eur Heart J,2010,31(24):3006-3016.
[11]American Diabetes Association.Standards of Medical Care in Diabetes--2010[J].Diabetes Care,2010,33(Suppl 1):S11-S61.
[12]Zhang K,Zhang J,Gao ZG,et al.Structure of the human P2Y12 receptor in complex with an antithrombotic drug[J].Nature,2014,509 (7498):115-118.
[13]Price MJ,Murray SS,Angiolillo DJ,et al.for the GIFT Investigators.Influence of genetic polymorphisms on the effect of high- and standarddose clopidogrel after percutaneous coronary intervention: the GIFT(Genotype Information and Functional Testing)study[J].J Am Coll Cardiol,2012,59(22):1928-1937.
[14]Hochholzer W,Trenk D,Fromm MF,et al.Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement[J].J Am Coll Cardiol,2010,55(22):2427-2434.
[15]Shuldiner AR,O’Connell JR,Bliden KP,et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009, 302(8):849-857.
[16]Ang L,Palakodeti V,Khalid A,et al.Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel[J].J Am Coll Cardiol,2008,52(13):1052-1059.
[17]Mega JL,Close SL,Wiviott SD,et al.Cytochrome-450 polymorphisms and response to lopidogrel[J].N Engl J Med,2009,360(4):354-362.
[18]Plavix package insert.Available at:http://products.sanofi.us/plavix/plavix.html. Accessed June 27,2014.
[19]Gurbel PA,Bliden KP,Butler K,et al.Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:The RESPOND study[J].Circulation,2010,121(10):1188-1199.
[20]Storey RF,Husted S,Harrington RA,et al.Inhibition of platelet aggregation by AZD6140,a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes[J].J Am Coll Cardiol,2007,50(19):1852-1856.
[21]Olivier CB,Schnabel K,Weber S,et al.Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel[J].J Thromb Thrombolysis,2016,42(1):84-89.
[22]Angiolillo DJ,Ferreiro JL,Price MJ,et al.platelet function and genetic testing[J].J Am Coll cardiol,2013,62 (17 Suppl):S21-S31.
[23]Parodi G,Marcucci R,Valenti R,et al.High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI[J].JAMA,2011,306(11):1215-1223.

备注/Memo

备注/Memo:

收稿日期：2016-05-24.基金项目：武汉市卫计委课题资助（WX14C78） 通讯作者：双东思，副主任医师,主要研究冠心病介入治疗 Email：sds97@163.com 作者简介：汪敏，副主任医师,硕士 Email：zeta331@aliyun.com

常用功能

更新日期/Last Update: 2017-02-20